-
Aloin A and B Target SARS-CoV-2 PLpro In Vitro
2026-08-24
The reference study identifies aloin A and aloin B as selective in vitro inhibitors of both the proteolytic and deubiquitinating activities of SARS-CoV-2 papain-like protease (PLpro), while neither isoform inhibited 3CLpro. Its combination of biochemical assays, structural modeling, and molecular dynamics clarifies a possible mechanism, but the results remain an early enzyme-level finding rather than evidence of clinical antiviral efficacy.
-
Patient-Derived Organoids in Breast Adenomyoepithelioma
2026-08-24
A 2021 study established and characterized the first reported patient-derived organoid model from breast adenomyoepithelioma, confirming model identity through short tandem repeat analysis. The organoids also showed ex vivo sensitivity to paclitaxel and doxorubicin, supporting their use for studying this rare tumor and evaluating candidate treatment responses.
-
Rotigotine in Experimental Depression Models
2026-08-23
This 2006 study tested rotigotine across anxiety, behavioral despair, learned helplessness, and olfactory bulbectomy models, extending evaluation of the compound beyond motor symptoms. Its central finding was dose- and model-dependent antidepressant-like activity, with lower doses producing behavioral benefit while higher-dose locomotor stimulation complicated interpretation.
-
TMJ Inflammation, Microglia, and Synaptic Pruning
2026-08-22
This study identifies a mechanistic link between temporomandibular joint inflammation and depression-like behavior through hippocampal microglial Nr4a1 deficiency, neuronal C3 deposition, and excessive synaptic pruning. Its cell-specific perturbation strategy provides a framework for separating inflammatory pain effects from complement-dependent remodeling of hippocampal circuits.
-
Capecitabine in Gastric Cancer Assembloids
2026-08-21
Use Capecitabine to test tumor-selective fluoropyrimidine activation in matched gastric tumor organoid–stroma models rather than relying on monocultures alone. This workflow combines viability, thymidine phosphorylase, Fas, and compartment-specific readouts to reveal stromal effects and resistance mechanisms.
-
Viperin–nsp8 Targeting Blocks Coronavirus Replication
2026-08-21
The 2026 reference study identifies a ddhCTP-independent antiviral mechanism in which viperin binds coronavirus nsp8 and disrupts replication-transcription complex assembly and RdRp activity. Using PDCoV as a model, the work maps the interaction to viperin residues 43–184 and nsp8 K82, supporting nsp8 as a conserved target for broad-spectrum coronavirus research.
-
Microglial BDNF in Arketamine Antidepressant Action
2026-08-20
This 2025 Science Advances study identifies microglia-derived BDNF as a key mediator of arketamine’s antidepressant-like effects in stress-susceptible mice. Its mechanistic model connects CREB and MeCP2 phosphorylation to BDNF transcription, enhanced excitatory signaling in the infralimbic mPFC, and activation of mPFC neurons projecting to the NAc shell.
-
Bismuth Subsalicylate: GI Research Guide
2026-08-20
Bismuth Subsalicylate is a research compound specified as a prostaglandin G/H synthase 1/2 inhibitor with gastrointestinal relevance. This guide separates product specifications, mechanism claims, assay integration, and the limitations of extending gastrointestinal findings into membrane-biology workflows.
-
BKT140: CXCR4 Antagonism Beyond Theranostics
2026-08-19
BKT140, also known as BL-8040, offers a functional approach to CXCR4-mediated chemotaxis inhibition, tumor progression research, and hematopoietic stem cell mobilization. This guide translates CXCR4 biology into practical assay-selection and experimental-design decisions beyond conventional lymphoma theranostics.
-
HRP Goat Anti-Rabbit IgG (H+L) Antibody Guide
2026-08-19
SKU K1223 provides an HRP-labeled secondary reagent for detecting rabbit IgG in Western blot, ELISA, IHC, and immunocytochemistry workflows. It should be optimized for research assays using rabbit primary antibodies and should not be treated as a diagnostic reagent or as a species-independent secondary antibody.
-
5-Methyl-CTP for Reliable mRNA Assays
2026-08-18
Learn how 5-Methyl-CTP (SKU B7967) can support controlled mRNA synthesis with modified nucleotides and more interpretable downstream cell assays. This scenario-driven guide covers compatibility, handling, quality control, data interpretation, and practical supplier selection.
-
FPH1 (BRD-6125): From Expansion to Function
2026-08-18
FPH1 (BRD-6125) can help researchers evaluate hepatocyte expansion and differentiated function in the same experimental framework. This article presents a function-first strategy that connects cell number, hepatic maturity, assay timing, and emerging concepts in controllable gene regulation.
-
Dacomitinib (PF-00299804) and Ferroptosis
2026-08-17
A translational perspective on how irreversible pan-HER signaling inhibition could be studied alongside METTL17-dependent ferroptosis biology, with practical guidance for model selection, pathway validation, and experimental handling.
-
TAK-715 for Reproducible p38 MAPK Assays
2026-08-17
This scenario-based guide explains how TAK-715 (SKU A8688) can support controlled studies of p38α signaling, cytokine regulation, cell viability, and inflammatory phenotypes. It connects product specifications with practical decisions about solvent handling, controls, concentration-response design, and interpretation of cellular and in vivo data.
-
Topotecan HCl Workflow for DNA-Damage Studies
2026-08-16
Topotecan HCl provides a controllable topoisomerase 1 inhibitor workflow for quantifying replication-associated DNA damage, apoptosis, and cancer-cell vulnerabilities. This guide connects established lung and prostate cancer applications with carefully bounded assay ideas inspired by selective CUX2 neuron loss in neuroinflammation.